Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05251922
Other study ID # MO19/127559
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2020
Est. completion date June 1, 2023

Study information

Verified date February 2022
Source The Leeds Teaching Hospitals NHS Trust
Contact Helen C Dearden
Phone 01132433144
Email helen.dearden1@nhs.net
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly.


Description:

This is a multicentre observational study evaluating frailty and tolerance of chemotherapy in the elderly. The number of people with cancer over the age of 65 years is increasing and more older patients are being treated with chemotherapy. Previous research has shown that patients living with frailty are more likely to experience significant toxicity from chemotherapy. A scoring system exists, the CARG (Cancer Aging Research Group) score), which using sociodemographics, tumour/treatment variables, laboratory test results (haemoglobin and creatinine clearance), geriatric assessment variables (function, co-morbidity, cognition, psychological state, social activity/support and nutritional status) predicts the likelihood of patients in this population developing a grade 3-5 toxicity. The CARG score ranges from 0 (lowest toxicity risk) to 19 (highest toxicity risk). This scoring system was developed and validated in the USA (United States of America). It was not however found to be predictive of toxicity in Australia. To date it has not been evaluated, nor is used in routine practice in oncology in the UK (United Kingdom). This study is looking at markers of frailty in patients >65years. The investigators seek to predict those who are at a higher risk of side effects from chemotherapy. The investigators are looking to validate the CARG score in a UK NHS (National Health Service) population and show feasibility of using this in routine practice. The investigators are also evaluating if other scoring systems which are routinely used to assess frailty (but have never been assessed for predicting toxicity) are useful in predicting toxicity. Secondary objectives include describing frailty in this population, exploring patients' perceptions of risk associated with chemotherapy and demonstrating the added value of risk prediction tools compared to clinicians estimates of toxicity risk.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date June 1, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Age >65years - About to start first line chemotherapy for a solid tumour based malignancy - Chemotherapy given for any intent eg. adjuvant or palliative - Estimated survival of >3months - Able to comprehend and complete questionnaire. Exclusion Criteria: - Medical or psychiatric condition impairing ability to consent - Participant is enrolled in another clinical trial - Prior chemotherapy for any indication - Receiving concurrent radiotherapy (RT) or immunotherapy (IT) - Unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Leeds NHS Teaching Hospitals Leeds

Sponsors (1)

Lead Sponsor Collaborator
The Leeds Teaching Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To validate the CARG scoring system To validate the CARG scoring system (a score which is calculated by the doctor using patient information) in a UK real-world population and show feasibility of implementing CARG scoring in routine NHS practice.
The investigators will collect the information required and calculate a CARG score for each participant.
The investigators will record Grade 3-5 chemotherapy toxicities (as assessed using CTCAEv5) for each participant.
The investigators will evaluate if the CARG score is predictive of Grade 3-5 toxicity (as assessed using CTCAEv5) in this UK real-world population.
The investigators will record how long it takes to collect this information and calculate the score to see if it is feasible to implement this in a real world setting.
6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - demographics The investigators are reporting demographics: age (years) and gender 6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - tumour type The investigators are reporting tumour type eg. breast cancer, gastric cancer etc. 6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - chemotherapy type The investigators will be reporting chemotherapy drugs delivered 6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - laboratory test results (Hb) The investigators will be reporting laboratory test results prior to first cycle of chemotherapy
-haemoglobin (g/L)
6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy - laboratory test results (CrCl) The investigators will be reporting laboratory test results prior to first cycle of chemotherapy
-creatinine clearance (mL/min)
6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy using SIOG (International Society of Geriatric Oncology) Geriatric Screening Tool (G8) Investigators will calculate the SIOG (International Society of Geriatric Oncology) Geriatric Screening Tool (G8) and report the score 6 months follow up
Secondary Describe frailty in elderly patients (>65years) in the UK NHS prior to starting chemotherapy using the Rockwood Clinical Frailty Score (CFS) Investigators will record the Rockwood Clinical Frailty Score (CFS) and report the scores 6 months follow up
Secondary Evaluate the predictive value of commonly used geriatric assessment tools in predicting chemotherapy tolerance Frailty scoring systems (G8 and CFS) will be calculated. Grade 3-5 chemotherapy toxicities will (as assessed using CTCAEv5) will be recorded.
The investigators will assess if these scoring systems have utility in predicting risk of grade 3-5 chemotherapy toxicity.
6 months follow up
Secondary The CARG score which reports the risk of grade 3-5 toxicity as assessed using CTCAEv5 as a percentage. 6 months follow up
Secondary Explore patients perception of risk associated with chemotherapy in this population Participants will report their perception of likelihood of developing a side effect from chemotherapy which would cause the participant to stay in hospital for one night or longer or have to stop treatment using the following options: Unlikely, Not very likely, Quite likely or Very likely, as well as using a percentage scale as seen below.
0 means I think it definitely won't happen to me ? 100 means I think I will definitely need to stop treatment or stay hospital at some point during my treatment
0-----10-----20-----30-----40-----50-----60-----70-----80-----90----100
6 months follow up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04992286 - Detection, Evaluation and Monitoring of Frailties in the Elderly (FRAGING) N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04061785 - Impact of Skills Acquired Through Judo Training on Risk Factors for Falling in Elderly Men and Women N/A
Completed NCT04140890 - Supporting Habit Formation to Attenuate Prefrailty in Elders: Pilot Study N/A
Recruiting NCT03141866 - Seated Physical Activity in Ageing N/A
Completed NCT04888884 - Loss of Independence - a Rapid Alternative to Frailty Screening in a Swedish ED Setting
Recruiting NCT04145726 - Frailty In Thoracic Surgery for Esophageal Cancer
Recruiting NCT04717869 - Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
Not yet recruiting NCT06022666 - PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery. N/A
Not yet recruiting NCT04514536 - Evaluation of a Health Monitoring Platform for Elderly in Home Care Context N/A
Completed NCT01126723 - Effects of Tai Chi on Frailty in Elderly Adults N/A
Completed NCT00183040 - HORMA: Hormonal Regulators of Muscle and Metabolism in Aging Phase 2
Active, not recruiting NCT05961319 - Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
Enrolling by invitation NCT05047731 - Antihypertensive Deprescribing in Long-term Care N/A
Completed NCT04956705 - Vitamin D and Calcium Supplementation at Danish Nursing Homes N/A
Recruiting NCT03824106 - Frailty Rehabilitation Phase 4
Recruiting NCT04518423 - Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
Completed NCT04087343 - Strength on Wheels: A Meal Delivery and Exercise Intervention for Homebound Older Adults N/A